在不完美的坚持场景下评估克洛扎的宽恕:一个人口药理动力学模拟研究
Archana Mishra1, Biswa Ranjan Mishra2, Debadatta Mohapatra2
1Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Naunyn-Schmiedeberg's archives of pharmacology
|September 10, 2025
概括
克洛扎 (耐治疗精神分裂症) 对遗漏剂量的宽恕率很低,需要严格遵守. 对剂量延迟存在中度耐受性,但在48小时后重新定位对于维持治疗水平至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 克洛扎对于耐治疗精神分裂症至关重要,但其治疗范围很窄.
- 由于副作用或后勤问题,克洛扎宾的不坚持是常见的.
- 药物对剂量错误的宽恕性尚未得到充分理解.
研究的目的:
- 模拟克洛扎的药理动力学,并评估其在各种剂量场景中的宽恕性.
- 量化错过或延迟剂量对克洛沙治疗疗效的影响.
主要方法:
- 开发并验证了克洛扎的单隔离药理动力学模型.
- 模拟评估了完美的坚持,遗漏剂量 (1-8),并在稳定状态下延迟 (1-10小时).
- 宽恕是根据曲线下的面积 (AUC) 和最低有效度 (MEC) 以上的时间来衡量的.
主要成果:
- 完美的坚持维持了治疗性克洛沙平水平 (0.44-0.62毫克/升).
- 错过的剂量显著降低了低谷值和AUC;八次错过的剂量导致接近零的水平.
- 10小时的延迟将AUC降低了71%和MEC以上的时间降低了43%,在150小时内恢复.
结论:
- 克洛沙平对遗漏剂量的宽恕率较低,强调需要严格遵守.
- 该药物对剂量延迟具有中等耐受性,这表明时间安排有一定的灵活性.
- 错过剂量的48小时后重新定位对于患者管理至关重要.
相关概念视频
Dosage Regimens: Partial Pharmacokinetic Parameters
155
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
155
Psychosis: Goals of Pharmacotherapy
476
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
476
Analysis of Population Pharmacokinetic Data
682
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
682
Drug Therapy
246
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
246
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
643
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
643
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
278
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
278


